SCHEMBL15537166

SCHEMBL15537166

COC(=O)c1scc(Br)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.42
ATM Q13315 1/20 0.42
KDM4E B2RXH2 3/20 0.41
GPR35 Q9HC97 1/20 0.41
KMT2A Q03164 6/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
MEN1 O00255 2/20 0.39
CYP2C19 P33261 1/20 0.39
GSK3B P49841 1/20 0.39
PTPN1 P18031 1/20 0.39
HTR1A P08908 1/20 0.38
SCN1A P35498 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
COMT P21964 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2987502 0.81 MAPT (0.49) MAPTPKMATMKDM4EKMT2A
SCHEMBL3306728 0.79 KMT2A (0.41) MAPTPKMATMKDM4EKMT2A
SCHEMBL1972551 0.78 PRKCZ (0.44) MAPTPKMATMKDM4EKMT2A
SCHEMBL1529989 0.78 MAPT (0.46) MAPTPKMATMKDM4EGPR35
SCHEMBL1760863 0.78 MAPT (0.43) MAPTPKMATMKDM4EKMT2A
SCHEMBL27472594 0.78 CYP1A2 (0.37) MAPTPKMATMKDM4EKMT2A
SCHEMBL25178620 0.77 SOS1 (0.43) MAPTPKMATMKDM4EKMT2A
SCHEMBL1529419 0.77 PTPN1 (0.44) MAPTPKMATMKDM4EKMT2A
SCHEMBL15057811 0.77 MAPT (0.42) MAPTPKMATMKDM4EKMT2A
SCHEMBL1845347 0.77 KDM4E (0.57) MAPTPKMATMKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10301272-B2 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] PHENEX PHARMACEUTICALS AG (DE) 2019-05-28 US disclosed
CN-104603118-B Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators of the orphan nuclear receptor ROR γ 菲尼克斯药品股份公司 2017-10-03 CN disclosed
CN-107007597-A It is used as the thiazole of orphan nuclear receptor ROR γ instrumentalities through formamide or sulfonamide substitutions and the pharmaceutical applications of related derivatives 菲尼克斯药品股份公司 2017-08-04 CN disclosed
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2015-06-25 US disclosed
EP-2855440-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] Phenex Pharmaceuticals AG (DE) 2015-04-08 EP disclosed
WO-2013178362-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2013-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] RORA, RORB, RORC MAPT 1422/4885PKM 3270/4885ATM 4778/4885
US-10301272-B2 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] RORA, RORB, RORC MAPT 1429/4885PKM 3215/4885ATM 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.